How can the quality of medical data in pharmacovigilance, pharmacoepidemiology and clinical studies be guaranteed?
Therapie. 2013 Jul-Aug;68(4):209-23.
doi: 10.2515/therapie/2013040.
Epub 2013 Aug 28.
[Article in
English,
French]
Authors
François Alla
1
, Myriam Rosilio, Christian Funck-Brentano; Participants of round table N° 2 of Giens Workshops XXVIII (th); Philippe Barthélémy, Sophie Brisset, Dominic Cellier, Olivier Chassany, Jean-Paul Demarez, Vincent Diebolt, Alain Francillon, Laetitia Gambotti, Hakima Hannachi, Philippe Lechat, François Lemaire, Michel Lièvre, Christophe Misse, Marina Nguon, Antoine Pariente, Michel Rosenheim, Nadine Weisslinger-Darmon
Affiliation
- 1 Université de Lorraine, Nancy, France.
Abstract
The development of medicinal products is subject to quality standards aimed at guaranteeing that database contents accurately reflect the source documents. Paradoxically, these standards hardly address the quality of the source data itself. The objective of this work was to propose recommendations to improve data quality in three fields (pharmacovigilance, pharmacoepidemiology and clinical studies). The analysis was focused on the data and on the critical stages presenting critical quality problems, for which the current guidelines are insufficiently detailed, unsuitable and/or poorly applied. Finally, recommendations have been proposed, mainly focused on the origin of the data and its transcription.
© 2013 Société Française de Pharmacologie et de Thérapeutique.
Publication types
-
Consensus Development Conference
MeSH terms
-
Adverse Drug Reaction Reporting Systems / standards
-
Clinical Trials as Topic*
-
Data Collection
-
Databases, Factual / standards*
-
Humans
-
Pharmacoepidemiology*
-
Pharmacovigilance*
-
Practice Guidelines as Topic
-
Quality Assurance, Health Care / methods*
-
Quality Assurance, Health Care / statistics & numerical data
-
Research Design / standards